EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [31] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2-metastatic breast cancer treated with a CDK4/6i in the first-line setting
    Behan, Emma
    Veenstra, David L.
    Bansal, Aasthaa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01): : 6 - 14
  • [32] Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
    Aftimos, P. G.
    Cortes, J.
    Bidard, F. C.
    Kaklamani, V.
    Bardia, A.
    Neven, P.
    Streich, G.
    Montero, A.
    Forget, F.
    Reynier, M. A. Mouret
    Sohn, J.
    Taylor, D.
    Harnden, K.
    Khong, H.
    Kocsis, J.
    Dalenc, F.
    Dillon, P.
    Tonini, G.
    Grzegorzewski, K. J.
    Lu, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S638 - S638
  • [33] Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
    Schettini, Francesco
    Palleschi, Michela
    Mannozzi, Francesca
    Braso-Maristany, Fara
    Cecconetto, Lorenzo
    Galvan, Patricia
    Mariotti, Marita
    Ferrari, Alessia
    Scarpi, Emanuela
    Miserocchi, Anna
    Nanni, Oriana
    Sanfeliu, Esther
    Prat, Aleix
    Rocca, Andrea
    De Giorgi, Ugo
    CANCER RESEARCH, 2024, 84 (09)
  • [34] Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
    Velimirovic, Marko
    Gerratana, Lorenzo
    Davis, Andrew A.
    Hensing, Whitney L.
    Clifton, Katherine
    Shah, Ami N.
    D'Amico, Paolo
    Dai, Charles S.
    Denault, Elyssa N.
    Ma, Cynthia X.
    Wander, Seth A.
    Juric, Dejan
    Cristofanilli, Massimo
    Chabner, Bruce A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [35] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [36] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [37] TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity
    Bagegni, Nusayba A.
    Grigsby, Isabella
    Nehring, Leslie
    Luo, Jingqin
    Carson, Jennifer Powers
    Gibson, David W.
    Horvath, Meghan
    Clifton, Katherine K.
    Ademuyiwa, Foluso O.
    Suresh, Rama
    Frith, Ashley
    Davis, Andrew A.
    Peterson, Lindsay L.
    Bose, Ron
    Williams, Amy
    Bergqvist, Mattias
    Ma, Cynthia
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy
    Arkadiusz Z. Dudek
    Li C. Liu
    James H. Fischer
    Elizabeth L. Wiley
    Jasgit C. Sachdev
    Jonathan Bleeker
    Randolph W. Hurley
    Debra A. Tonetti
    Gregory R. J. Thatcher
    Robert P. Venuti
    Ruth M. O’Regan
    Breast Cancer Research and Treatment, 2020, 183 : 617 - 627
  • [39] Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy
    Dudek, Arkadiusz Z.
    Liu, Li C.
    Fischer, James H.
    Wiley, Elizabeth L.
    Sachdev, Jasgit C.
    Bleeker, Jonathan
    Hurley, Randolph W.
    Tonetti, Debra A.
    Thatcher, Gregory R. J.
    Venuti, Robert P.
    O'Regan, Ruth M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 617 - 627
  • [40] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
    Dickler, Maura N.
    Tolaney, Sara M.
    Rugo, Hope S.
    Cortes, Javier
    Dieras, Veronique
    Patt, Debra
    Wildiers, Hans
    Hudis, Clifford A.
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Frenzel, Martin
    Koustenis, Andrew
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5218 - 5224
12345